Tan, Yunfei
Fujita, Yuko
Pu, Yaoyu
Chang, Lijia
Qu, Youge
Wang, Xinming
Hashimoto, Kenji http://orcid.org/0000-0002-8892-0439
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20dm0107119)
Article History
Received: 11 October 2021
Accepted: 24 November 2021
First Online: 3 January 2022
Declarations
:
: Dr. Hashimoto is the inventor of filed patent applications on “The use of <i>R</i>-ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, “<i>R</i>-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases”, and “TGF-β1 in the treatment of depression” by the Chiba University. Dr. Hashimoto also declares that he has received research support and consultant from Dainippon Sumitomo, Otsuka, Taisho, Murakami Farm, and Perception Neuroscience. The other authors have no conflict of interest.